178 related articles for article (PubMed ID: 16755223)
21. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
22. Genetic studies in acute lymphoblastic leukemia.
Pui CH
Acta Paediatr Taiwan; 2000; 41(6):303-7. PubMed ID: 11198935
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
24. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.
Asselin BL; Gaynon P; Whitlock JA
Curr Opin Oncol; 2013 Dec; 25 Suppl 3():S1-13; quiz S14-6. PubMed ID: 24305505
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
27. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui CH
Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
[TBL] [Abstract][Full Text] [Related]
28. Risk-adapted treatment of pediatric acute lymphoblastic leukemia.
Jeha S; Pui CH
Hematol Oncol Clin North Am; 2009 Oct; 23(5):973-90, v. PubMed ID: 19825448
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
30. Biology and treatment of acute lymphoblastic leukemia.
Pieters R; Carroll WL
Pediatr Clin North Am; 2008 Feb; 55(1):1-20, ix. PubMed ID: 18242313
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.
Eckert C; Biondi A; Seeger K; Cazzaniga G; Hartmann R; Beyermann B; Pogodda M; Proba J; Henze G
Lancet; 2001 Oct; 358(9289):1239-41. PubMed ID: 11675066
[TBL] [Abstract][Full Text] [Related]
33. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.
Umerez M; Garcia-Obregon S; Martin-Guerrero I; Astigarraga I; Gutierrez-Camino A; Garcia-Orad A
Pharmacogenomics; 2018 Mar; 19(4):361-373. PubMed ID: 29469670
[TBL] [Abstract][Full Text] [Related]
34. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
35. The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer.
Burke GA; Estlin EJ; Lowis SP
Cancer Treat Rev; 1999 Feb; 25(1):13-27. PubMed ID: 10212587
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of acute lymphoblastic leukemia.
Mehta PA; Davies SM
Curr Opin Hematol; 2004 Nov; 11(6):434-8. PubMed ID: 15548999
[TBL] [Abstract][Full Text] [Related]
37. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):699-719. PubMed ID: 24673379
[TBL] [Abstract][Full Text] [Related]
39. [Results of the National Protocol for Antineoplastic Drugs in the treatment of adult acute lymphoblastic leukemia. Experience at the Hospital del Salvador, 1990-1997].
Puga B; Cabrera ME; Undurraga MS
Rev Med Chil; 1998 Sep; 126(9):1093-9. PubMed ID: 9922513
[TBL] [Abstract][Full Text] [Related]
40. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Henze G; v Stackelberg A; Eckert C
Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
